GSK EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
GSK's ev/ebitda is lower than 95% of the last 10 years.
EV/EBITDA History
GSK EV/EBITDA by year
Yearly range of GSK’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 7.0 to 27.6, averaging 10.8.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 7.5 | 8.6 | 9.7 | 8.1 |
| 2025 | 7.7 | 9.6 | 11.7 | 7.7 |
| 2024 | 8.9 | 10.2 | 11.3 | 10.4 |
| 2023 | 7.7 | 8.3 | 9.2 | 8.0 |
| 2022 | 8.8 | 10.9 | 13.1 | 9.8 |
| 2021 | 7.0 | 8.6 | 12.6 | 12.6 |
| 2020 | 7.5 | 9.5 | 10.8 | 7.5 |
| 2019 | 9.5 | 10.4 | 11.6 | 10.5 |
| 2018 | 10.7 | 13.5 | 15.9 | 11.0 |
| 2017 | 9.5 | 13.6 | 17.6 | 9.7 |
| 2016 | 21.7 | 23.6 | 27.6 | 22.2 |
Get notified when GSK EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is GSK EV/EBITDA High or Low Right Now?
GSK plc's EV/EBITDA is currently 8.1, which is near historic low relative to its 10-year historical range. The 10-year median EV/EBITDA for GSK is approximately 10.0. See all GSK valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.